

Supplemental Material

Andrographolide Protects Against Adverse Cardiac Remodeling After Myocardial Infarction Through Enhancing Nrf2 Signaling Pathway

Saiyang Xie^{1,2}, Wei Deng^{1,2*}, Jiaojiao Chen³, Qing-Qing Wu^{1,2}, Hongjian Li⁴, Juan Wang⁴, Li Wei³, Chen Liu^{1,2}, Mingxia Duan^{1,2}, Zhulan Cai^{1,2}, Qingwen Xie^{1,2}, Tongtong Hu^{1,2}, Xiaofeng Zeng^{1,2}, Qizhu Tang^{1,2}

SUPPLEMENTARY INFORMATION

Table.1 Primer information for QPCR analysis of expression of target genes

Gene	Species	Forward primer (5'→3')	Reverse primer (5'→3')
ANP	Mouse	ACCTGCTAGACCACCTGGAG	CCTTGGCTGTTATCTTCGGTACCGG
BNP	Mouse	GAGGTCACCTCTATCCTCTGG	GCCATTTCTCCGACTTTTCTC
β-MHC	Mouse	CCGAGTCCCAGGTCAACAA	CTTACGGGCACCCTTGGA
Collagen I	Mouse	AGGCTTCAGTGGTTTGGATG	CACCAACAGCACCATCGTTA
CTGF	Mouse	AGGGCCTCTTCTGCGATTC	CTTTGGAAGGACTCACCGCT
IL 1β	Mouse	TGGTACATCAGCCGAAC	GTCAGCTGGATAGCGACA
IL6	Mouse	GTCAGCTGGATAGCGACA	GAAGCACAGGAGCAGGTGTAGA
TNFα	Mouse	GACATGCCGCTGGAGAAAC	AGCCCAGGATGCCCTTAGT
MCP1	Mouse	TGGCTCAGCCAGATGCAGT	CCAGCCTACTCATTGGGATCA
Gp 91	Mouse	TTCCAGTGCCTGTTGCTCGACA	TGGCGGTGTGCAGTGCTATCAT
P67 phox	Mouse	GCCGGAGACGCCAGAAGAGCTA	GGGGCTGCGACTGAGGGTGAA
NOX4	Mouse	ATGTTGGGCCTAGGATTGTGTT	GGCTACATGCACACCTGAGA
Gpx	Mouse	GAGAATGGCAAGAATGAAGAG	GAAGGTAAAGAGCGGGTGA
SOD2	Mouse	CCGTCCGTGTGCGCCGTCCTC	GCCGCGTGGTGCTTGCTGTG
NQO1	Mouse	CCAATCAGCGTTCCGGTATTA	GTCTTCTCTGAATGGGCCAG
Nrf2	Mouse	ATGATGGACTTGGAGTTGCC	TCCTGTTCTTCTGGAGTTG
HO-1	Mouse	AGGAGATAGAGCGCAACAAGCAG	CCAGTGAGGCCCATACCAGAAG
Collagen I	Rat	GAGAGAGCATGACCGATGGATT	TGGACATTAGGCGCAGGAA
CTGF	Rat	GGAAGACACATTTGGCCCTG	GGAAGACACATTTGGCCCTG
Fibronectin	Rat	CCGGTGGCTGTCAGTCAGA	CCGTTCCCACTGCTGATTTATC
Nrf2	Rat	AGATGACCATGAGTCGCTTGCCCT	TCAGCCTGCTGCTTGTTTTCCGT
HO-1	Rat	CGCATGAACACTCTGGAGATG	TGTGAGGGACTCTGGTCTTTGT
SOD2	Rat	AGCCTCCCTGACCTGCCTTA	CGCCTCGTGGTACTTCTCCTC
NQO1	Rat	TCCGAAGCATTTCAGGGTCG	GGCCAATACAATCAGGGCT
Gp 91	Rat	TGAATCTCAGGCCAATCACTTT	AATGGTCTTGAACCTGTTATCCC
P67 phox	Rat	TGCTGCTCCTGTCAGAAGAA	CACCTGGGTCCCTTCCTTAG

Fig. 1




Fig. 1 Cardiac fibroblasts are treatment with or without tri-gas incubator (Panasonic, Japan) and treated with different concentrations of Andr (0, 12.5, 25, or 50 μM). **A.** Cell viability was accessed by the cell counting kit-8 assay in 96-well plate (n = 6 per groups). **B.** Cell proliferation was accessed by the cell counting kit-8 assay in 96-well plate (n = 6 per groups). The results are presented as a fold change, and the data are given as the mean \pm SEM.* $P < 0.05$ compared with the control group. # $P < 0.05$ vs. the hypoxia without Andr group.

Fig.2




Fig. 2 H9C2 Cardiomyocytes are treatment with or without tri-gas incubator (Panasonic, Japan) and treated with different concentrations of Andr (0, 12.5, 25, or 50 μ M). **A.** Cell viability was accessed by the cell counting kit-8 assay in 96-well plate (n = 6 per groups). **B-G.** The relative mRNA expression of Nrf2, HO-1, SOD2, NQO1, Gp91 and NADPH p67 phox (n=6). And the data are given as the mean \pm SEM.* P < 0.05 compared with the control group. # P < 0.05 vs. the hypoxia without Andr group.

Fig.3






Fig. 3 H9C2 Cardiomyocytes are transfected with siRNA for Nrf2 or Nrf2 inhibitor ML385 for 24h, followed by treatment with tri-gas incubator (Panasonic, Japan) or Andr for another 24h. **A.** Cell viability was accessed by the cell counting kit-8 assay in 96-well plate (n = 6 per groups). **B.** The result of western blot showed the expression level of Nrf2 with Nrf2 siRNA or scRNA (shRNA control) and ML385 or DMSO. **C-F.** The relative mRNA expression of Nrf2 and HO-1 in indicated condition in vitro. *P < 0.05 compared with the control group. # P < 0.05 vs. the hypoxia without Andr group.